X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs DIVIS LABORATORIES - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA DIVIS LABORATORIES ABBOTT INDIA/
DIVIS LABORATORIES
 
P/E (TTM) x 37.1 34.7 106.8% View Chart
P/BV x 9.5 6.8 141.4% View Chart
Dividend Yield % 0.7 0.7 108.8%  

Financials

 ABBOTT INDIA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
DIVIS LABORATORIES
Mar-18
ABBOTT INDIA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6,1101,142 535.1%   
Low Rs3,996533 749.6%   
Sales per share (Unadj.) Rs1,552.2146.6 1,058.9%  
Earnings per share (Unadj.) Rs188.833.0 571.5%  
Cash flow per share (Unadj.) Rs196.438.4 511.5%  
Dividends per share (Unadj.) Rs55.0010.00 550.0%  
Dividend yield (eoy) %1.11.2 91.2%  
Book value per share (Unadj.) Rs796.6222.8 357.5%  
Shares outstanding (eoy) m21.25265.47 8.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.35.7 57.0%   
Avg P/E ratio x26.825.3 105.6%  
P/CF ratio (eoy) x25.721.8 118.0%  
Price / Book Value ratio x6.33.8 168.8%  
Dividend payout %29.130.3 96.2%   
Avg Mkt Cap Rs m107,376222,318 48.3%   
No. of employees `0003.310.8 30.9%   
Total wages/salary Rs m3,9374,561 86.3%   
Avg. sales/employee Rs Th9,929.33,616.0 274.6%   
Avg. wages/employee Rs Th1,185.1423.8 279.7%   
Avg. net profit/employee Rs Th1,207.7814.9 148.2%   
INCOME DATA
Net Sales Rs m32,98538,915 84.8%  
Other income Rs m1,1701,134 103.1%   
Total revenues Rs m34,15540,049 85.3%   
Gross profit Rs m5,24512,617 41.6%  
Depreciation Rs m1621,425 11.4%   
Interest Rs m3813 287.2%   
Profit before tax Rs m6,21512,313 50.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2033,543 62.2%   
Profit after tax Rs m4,0128,770 45.7%  
Gross profit margin %15.932.4 49.0%  
Effective tax rate %35.428.8 123.2%   
Net profit margin %12.222.5 54.0%  
BALANCE SHEET DATA
Current assets Rs m22,65545,351 50.0%   
Current liabilities Rs m6,6816,507 102.7%   
Net working cap to sales %48.499.8 48.5%  
Current ratio x3.47.0 48.7%  
Inventory Days Days65127 51.1%  
Debtors Days Days2995 30.6%  
Net fixed assets Rs m83521,160 3.9%   
Share capital Rs m213531 40.0%   
"Free" reserves Rs m16,71558,625 28.5%   
Net worth Rs m16,92859,156 28.6%   
Long term debt Rs m00-   
Total assets Rs m24,16267,832 35.6%  
Interest coverage x163.7926.8 17.7%   
Debt to equity ratio x00-  
Sales to assets ratio x1.40.6 238.0%   
Return on assets %16.812.9 129.5%  
Return on equity %23.714.8 159.9%  
Return on capital %36.920.8 177.3%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m36932,359 1.1%   
Fx outflow Rs m3,8079,042 42.1%   
Net fx Rs m-3,43823,317 -14.7%   
CASH FLOW
From Operations Rs m1,5277,759 19.7%  
From Investments Rs m-2,148-4,783 44.9%  
From Financial Activity Rs m-1,024-3,142 32.6%  
Net Cashflow Rs m-1,646-166 991.3%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 11.8 66.9%  
FIIs % 0.1 19.0 0.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 17.2 99.4%  
Shareholders   18,270 31,796 57.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   NATCO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Nov 14, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS